Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
•
SABCS 2025
Will the results of Alliance A011104/ACRIN 6694 change your current practice regarding preoperative MRI’s in patients with newly-diagnosed, early stage breast cancer?
Related Questions
What potential challenges do you foresee in transitioning from current endocrine therapies to giredestrant, based on the lidERA trial results, in ER+, HER2- early breast cancer?
How will the LORETTA and COMET trials influence your treatment of low-risk DCIS?
What are your top takeaways in Medical Oncology from SABCS 2025?
What are your top takeaways in Radiation Oncology from SABCS 2025?
How do the ALTTO trial findings influence your choice of adjuvant endocrine therapy (AI with or without ovarian function suppression versus SERM-based therapy) for patients with HR+/HER2+ early breast cancer?
In patients with newly diagnosed HER2+ early breast cancer, what do you anticipate will become the standard sequencing for T-DXd, neoadjuvant (DB11) or adjuvant (DB05) treatment?
What additional risk features, if any, would sway you to offer chemotherapy in premenopausal women with ER+ HER2- node positive patients whose Oncotype is < 11?
What adjuvant therapy would you recommend for a woman in her 90s with ER-positive, HER2-positive breast cancer who received neoadjuvant trastuzumab, pertuzumab, and anastrozole, but did not achieve a pathologic complete response?
Would you consider adding adjuvant ribociclib for a patient who has already received 2 years of endocrine therapy and is eligible for ribociclib according to the NATALEE trial?
In the current era of adjuvant CDK4/6 inhibitor use for high-risk HR+/HER2-negative breast cancer, what is the preferred adjuvant chemotherapy regimen for premenopausal women — AC-T or TC?
